A new state-by-state report reveals that while lung cancer survival rates are improving, it remains the deadliest cancer in the United States.
Although we've made strides, much more needs to be done. Harold Wimmer, President and CEO of the American Lung Association (ALA), expressed his optimism over the future of lung cancer care. In addition to highlighting improvements in survival rates, the organization's 2024 State of Lung Cancer report outlines important areas for further progress.
Over the past five years, the lung cancer survival rate has risen by 26%, a development largely attributed to the adoption of biomarker testing. This testing identifies genetic changes in a tumor's DNA, enabling personalized treatment strategies. However, access to this life-saving technology remains uneven, as only 15 states mandate comprehensive insurance coverage for biomarker testing, while five additional states require limited coverage.
According to a press release, Wimmer said, "This year's State of Lung Cancer report outlines actionable steps for states and the federal government to improve outcomes for those affected by this devastating disease." "Improving access to biomarker testing and raising lung cancer screening rates are vital chances to identify cancer early and give patients the best care possible."
The study offers a thorough examination of lung cancer screening rates by state and nationally. Only sixteen percent of eligible people in the US were screened in 2023. Wyoming had the lowest screening rate (8.6%), while Rhode Island had the highest (28.6%). Nearly 235,000 new cases of lung cancer are expected to be diagnosed nationwide this year, according to the report.
Early diagnosis remains a challenge, with only 27.4% of cases detected at an early stage, when the five-year survival rate is significantly higher at 64%. Unfortunately, 43% of cases are identified at a late stage, when the survival rate drops sharply to 9%. Massachusetts had the best early diagnosis rate (34.7%), while Hawaii had the lowest (21.1%).
Treatment patterns also vary, with surgery being a common approach for early-stage lung cancer. Nationwide, 20.7% of cases were treated surgically. However, 20.9% of cases received no treatment at all, often due to factors such as lack of awareness, stigma, or financial barriers. Nevada reported the highest rate of untreated cases (36.7%), while Massachusetts had the lowest (13.2%).
Disparities in outcomes persist, particularly among minorities, who are less likely to be diagnosed early, undergo surgery, or receive any treatment compared to White patients. “Addressing lung cancer health disparities must be a priority,” the ALA emphasized, calling for all states to require insurance coverage for biomarker testing.
The report concludes with a call to action, urging policymakers and healthcare providers to take bold steps toward improving lung cancer care and ensuring equitable access to life-saving advancements.
No comments:
Post a Comment